Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268375 | PMC |
| http://dx.doi.org/10.2147/IDR.S433652 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacodynamic target attainment of the synergism of ceftazidime-avibactam in combination with amikacin against OXA-producing extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa.
Eur J Clin Microbiol Infect Dis
March 2025
Nankai University, Tianjin, China.
To investigate the pharmacodynamic target attainment of ceftazidime-avibactam (CZA) in combination with amikacin against OXA-producing extensively drug-resistant/ pan-drug-resistant Pseudomonas aeruginosa (XDR/PDR-PA). The minimum inhibitory concentrations (MICs) of CZA and amikacin against OXA-producing XDR/PDR-PA were determined by the checkerboard method, and the combined inhibitory index (FICI) was calculated to evaluate whether the combination of the two antimicrobials has a synergistic effect on OXA-producing XDR/PDR-PA in vitro. The pharmacokinetic (PK) and pharmacodynamic (PD) parameters of CZA and amikacin were combined by Monte Carlo simulation (MCS) to evaluate the cumulative fraction of response (CFR) of the two antimicrobials for the treatment of OXA-producing XDR/PDR-PA infection.
View Article and Find Full Text PDFIn vitro synergistic effects of mefloquine combined with other antimicrobial agents on carbapenem-resistant Enterobacterales.
Eur J Clin Microbiol Infect Dis
February 2025
Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Purpose: Human health is seriously threatened by carbapenem-resistant Enterobacterales (CRE) due to the lack of effective treatment. The purpose of this study is to examine the efficacy of mefloquine (MEF) together with multiple drugs against 96 clinical CRE isolates including 94 Klebsiella pneumoniae carbapenemase (KPC)-producers or Metallo-β-lactamases (MBLs)-producers and 2 colistin antibiotic resistance enzyme MCR-1-producers.
Methods: Using the broth microdilution method, MICs of MEF in combination with multiple antimicrobial agents, including colistin (COL), imipenem, aztreonam-avibactam (ATM-AVI), ceftazidime-avibactam (CAZ-AVI) for 96 CRE isolates were determined.
Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime/avibactam plus aztreonam therapy.
Eur J Clin Microbiol Infect Dis
February 2025
Infectious Diseases Service, Hospital del Mar, Passeig Marítim 25-29, Barcelona, 08003, Spain.
This study evaluated the activity of cefiderocol and the combination of ceftazidime/avibactam (CZA) plus aztreonam against carbapenemase-producing extensively drug-resistant (XDR) Pseudomonas aeruginosa isolates. Nine clinical XDR P. aeruginosa isolates with different sequence types and class A (GES) or B (VIM, IMP or NDM) carbapenemases were analysed.
View Article and Find Full Text PDFSynergistic combination of ceftazidime and avibactam with Aztreonam against MDR Klebsiella pneumoniae in ICU patients.
Sci Rep
February 2025
Microbiology and Immunology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
The proliferation of multidrug-resistant, metallo-beta-lactamase-producing Klebsiella pneumoniae (MBL-producing K. pneumoniae) poses a major threat to public health resulting in increasing treatment costs, prolonged hospitalization, and mortality rate. Treating such bacteria presents substantial hurdles for clinicians.
View Article and Find Full Text PDFEffectiveness of antimicrobial agent combinations against carbapenem-producing with KPC variants in China.
Front Microbiol
January 2025
Department of Clinical Laboratory, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
Purpose: Carbapenem-resistant (CRKP) producing carbapenemases poses a global threat to public health. Antimicrobial agent combinations have been promoted as a potential therapeutic strategy for infections. The most effective antimicrobial combinations against CRKP strains producing different carbapenemases are currently unclear, particularly those producing the KPC variant carbapenemases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!